{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000097","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.242695+00:00","generated_at":"2026-05-16T17:35:19.520801+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity","bullets":["Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.","Anaptys has repurchased 3,443,188 shares (11.2% of shares outstanding) under the plan to date.","Company expects ~$300M cash end-2025, including anticipated $75M commercial milestone from GSK on Jemperli reaching $1B sales.","Plan expires March 31, 2026; repurchases depend on market conditions and regulatory limitations."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000097","json":"https://secwatch.observer/filing/0001370053-25-000097.json","markdown":"https://secwatch.observer/filing/0001370053-25-000097.md","text":"https://secwatch.observer/filing/0001370053-25-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000097/0001370053-25-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000097/anab-20251121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:35:19.520801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}